Abstract:Cardiac fibrosis is a serious health problem because it is a common pathological change in almost all forms of cardiovascular diseases. Cardiac fibrosis is characterized by the transdifferentiation of cardiac fibroblasts (CFs) into cardiac myofibroblasts and the excessive deposition of extracellular matrix (ECM) components produced by activated myofibroblasts, which leads to fibrotic scar formation and subsequent cardiac dysfunction. However, there are currently few effective therapeutic strategies protecting against fibrogenesis. This lack is largely because the molecular mechanisms of cardiac fibrosis remain unclear despite extensive research. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling cascade is an extensively present intracellular signal transduction pathway and can regulate a wide range of biological processes, including cell proliferation, migration, differentiation, apoptosis, and immune response. Various upstream mediators such as cytokines, growth factors and hormones can initiate signal transmission via this pathway and play corresponding regulatory roles. STAT3 is a crucial player of the JAK/STAT pathway and its activation is related to inflammation, malignant tumors and autoimmune illnesses. Recently, the JAK/STAT3 signaling has been in the spotlight for its role in the occurrence and development of cardiac fibrosis and its activation can promote the proliferation and activation of CFs and the production of ECM proteins, thus leading to cardiac fibrosis. In this manuscript, we discuss the structure, transactivation and regulation of the JAK/STAT3 signaling pathway and review recent progress on the role of this pathway in cardiac fibrosis. Moreover, we summarize the current challenges and opportunities of targeting the JAK/STAT3 signaling for the treatment of fibrosis. In summary, the information presented in this article is critical for comprehending the role of the JAK/STAT3 pathway in cardiac fibrosis, and will also contribute to future research aimed at the development of effective anti-fibrotic therapeutic strategies targeting the JAK/STAT3 signaling.

Glycogen synthase kinase-3: a promising candidate in the fight against fibrosis

Glycogen synthase kinase-3β: a promising candidate in the fight against fibrosis.

JAK/STAT3 Signaling in Cardiac Fibrosis: a Promising Therapeutic Target

GSK3β-dependent Lysosome Biogenesis: an Effective Pathway to Mitigate Renal Fibrosis with LM49

Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities

Permissive Effect of GSK3β on Profibrogenic Plasticity of Renal Tubular Cells in Progressive Chronic Kidney Disease.

TGF2 and TGF3 isoforms drive fibrotic disease pathogenesis

Transforming growth factor- signaling: From tissue fibrosis to therapeutic opportunities

Epigenetics As a Versatile Regulator of Fibrosis

Early Growth Response Transcription Factors: Key Mediators of Fibrosis and Novel Targets for Anti-Fibrotic Therapy

G Protein-Coupled Receptor Kinase 2 as Novel Therapeutic Target in Fibrotic Diseases

FOXO1/3: Potential suppressors of fibrosis.

FOXO1/3: Potential Suppressors of Fibrosis

Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis

The role of JNK signaling pathway in organ fibrosis

TRIB3‒GSK-3β interaction promotes lung fibrosis and serves as a potential therapeutic target

Epigenetics and Fibrosis

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies

Advances in the Therapeutic Potential of Inhibitors Targeting Glycogen Synthase Kinase 3 in Inflammatory Diseases

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

Kidney Fibrosis: from Mechanisms to Therapeutic Medicines